Eli Lilly and Company (NYSE:LLY) Shares Purchased by Rock Springs Capital Management LP

Rock Springs Capital Management LP grew its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 1.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 144,500 shares of the company's stock after purchasing an additional 2,500 shares during the period. Eli Lilly and Company makes up 4.2% of Rock Springs Capital Management LP's holdings, making the stock its 3rd largest position. Rock Springs Capital Management LP's holdings in Eli Lilly and Company were worth $111,554,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Eli Lilly and Company by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 74,248,997 shares of the company's stock worth $57,320,226,000 after buying an additional 475,530 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Eli Lilly and Company by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company's stock valued at $13,389,651,000 after acquiring an additional 291,875 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of Eli Lilly and Company by 19.0% in the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock worth $9,747,214,000 after acquiring an additional 2,012,129 shares during the period. Norges Bank acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $8,407,908,000. Finally, Capital Research Global Investors raised its holdings in shares of Eli Lilly and Company by 16.1% during the fourth quarter. Capital Research Global Investors now owns 10,757,511 shares of the company's stock worth $8,304,811,000 after purchasing an additional 1,493,673 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.13% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

LLY has been the topic of several recent research reports. Guggenheim lowered their price target on shares of Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research note on Friday, January 17th. Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a report on Tuesday. They set an "overweight" rating and a $975.00 target price on the stock. Truist Financial boosted their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a report on Monday, February 3rd. Finally, Wells Fargo & Company raised their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Two investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1,017.00.

Eli Lilly and Company Price Performance

LLY stock traded up $31.69 during trading on Thursday, hitting $861.11. The stock had a trading volume of 2,936,578 shares, compared to its average volume of 3,430,652. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company's 50-day moving average price is $826.81 and its two-hundred day moving average price is $819.07. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The stock has a market capitalization of $816.48 billion, a P/E ratio of 73.54, a PEG ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.